Table 9.
Data of pathological small fiber tests.
| FMS | SFN | P | |
|---|---|---|---|
| Skin biopsy | |||
| IENFD distally reduced (ie, <5.4 fibers/mm) | 18/158 (11.4%) | 10/53 (18.9%) | n.s. |
| IENFD proximally reduced (ie, <8.5 fibers/mm) | 48/157 (30.6%) | 8/53 (15.1%) | <0.05 |
| IENFD generally reduced (ie, distal <5.4 fibers/mm AND proximal <8.5 fibers/mm) | 38/158 (24.1%) | 13/53 (24.5%) | n.s. |
| Pathological IENFD in at least one localization | 104/157 (66.2%) | 31/53 (58.5%) | n.s. |
| QST pathological16 | |||
| CDT | 6/157 (3.8%) | 10/53 (18.9%) | <0.01 |
| WDT | 13/157 (8.3%) | 10/53 (18.9%) | <0.05 |
| TSL | 18/157 (11.5%) | 15/53 (28.3%) | <0.01 |
| QST (ie, CDT, WDT, or TSL pathological) | 24/157 (15.3%) | 19/53 (35.8%) | <0.01 |
| PHS | 32/157 (20.4%) | 18/53 (34.0%) | n.s. |
| CPT | 0/157 (0%) | 2/53 (3.8%) | n.s. |
| HPT | 16/156 (10.3%) | 7/53 (13.2%) | n.s. |
| MDT | 13/157 (8.3%) | 10/53 (18.9%) | <0.05 |
| MPT | 25/157 (15.9%) | 16/53 (30.2%) | <0.05 |
| MPS | 34/156 (21.8%) | 12/52 (23.1%) | n.s. |
| DMA | 14/157 (8.9%) | 2/52 (3.8%) | n.s. |
| WUR | 6/157 (3.8%) | 4/52 (7.7%) | n.s. |
| VDT | 18/157 (11.5%) | 3/53 (5.7%) | n.s. |
| PPT | 23/157 (14.6%) | 4/53 (7.5%) | n.s. |
| CCM | |||
| Pathological NFD (ie, <19.3/mm2) | 34/133 (25.6%) | 11/50 (22.0%) | n.s. |
| Pathological NBD (ie, <36.3/mm2) | 15/133 (11.3%) | 18/50 (36.0%) | <0.001 |
| Pathological NFL (ie, <11.1 mm/mm2) | 33/133 (24.8%) | 14/50 (28.0%) | n.s. |
| At least one pathological CCM parameter | 47/133 (35.3%) | 22/51 (43.1%) | n.s. |
| PREP | |||
| Pathological N1 (ie, >224.89 ms) | 3/123 (2.4%) | 14/39 (35.9%) | <0.001 |
| Pathological P1 (ie, >285.46 ms) | 2/123 (1.6%) | 15/39 (38.5%) | <0.001 |
| Pathological PPA (ie, <10.0 µV) | 51/123 (41.5%) | 7/38 (18.4%) | <0.05 |
| At least one pathological PREP parameter | 52/123 (42.3%) | 21/39 (53.8%) | n.s. |
CCM, corneal confocal microscopy; CDT, cold detection threshold; CPT, cold pain threshold; DMA, dynamic mechanical allodynia; FMS, fibromyalgia syndrome; HbA1c, glycated hemoglobin A1c; HPT, heat pain threshold; IENFD, intraepidermal nerve fiber density; MDT, mechanical detection threshold; MPT, mechanical pain threshold; MPS, mechanical pain sensitivity; N1, first negative peak latency; NBD, nerve branch density; NFD, nerve fiber density; NFL, nerve fiber length; n.s., not significant; oGTT, oral glucose tolerance test; P1, subsequent positive peak latency; NRS, numeric rating scale; PHS, paradoxical heat sensations; PPA, peak-to-peak amplitudes; PPT, pressure pain threshold; PREP, pain-related evoked potentials; QST, quantitative sensory testing; SFN, small fiber neuropathy; TSH, thyroid-stimulating hormone; TSL, thermal sensory limen; VDT, vibration detection threshold; WDT, warm detection threshold; WUR, wind-up ratio.